RxDoctor Payments DataLook up a doctor →

Howard Lazarus, MD

Retina Specialist · New Albany, INNPI 1063411635

Payments from drug & device makers

$891,988in general payments, 2019–2025

Across 130 payments — averaging $6861.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$815K
  • Regeneron$54K
  • AstraZeneca$14K
  • AbbVie$7K
  • Novo Nordisk AS$841
  • Regeneron Healthcare Solutions, Inc.$511
  • plus $1K from 17 others
$6,171in research payments, 2019–2025

Across 11 payments — averaging $561.04 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Bausch Health US, LLC$4K
  • Regeneron$2K

What the payments were for

  • Travel & lodging$70824%
  • Food & beverage$2,28376%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$891,988 in reported general payments places this provider in the 90th percentile of 21 retina specialist providers in Indiana.

See all retina specialist providers in Indiana

Medicare billing

Part B allowed, 2024
$2,739,974
Medicare patients
741
Services billed
28,855

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost55$25,243
RestasisCyclosporine29$24,715
CombiganBrimonidine Tartrate/Timolol41$9,642
Prednisolone Acetate158$4,574
Difluprednate50$3,694
Latanoprost236$2,315
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol16$2,211
Brimonidine Tartrate130$1,590
Timolol Maleate93$950
Ciprofloxacin Hcl90$934
Dorzolamide Hcl27$467
Ketorolac Tromethamine22$440
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat40$430
Diclofenac Sodium14$173

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan$6,748$59,600125 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 21 retina specialist providers in Indiana.

Other retina specialist in New Albany

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →